Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Log In
Skip to content
?
The Company protects its technology through an aggressive strategy to cover its intellectual property. The Company’s intellectual property includes:
Issued Patents
Enzolytics is the owner of the following issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo.
U.S. Patent No. 7,479,538, issued January 20, 2009, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing and Treating HIV
U.S. Patent No. 8,066,982, issued November 29, 2011, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing, and Treating HIV.
These patents cover an Inactivated Pepsin Fragment (IPF) identified and characterized by the amino acid sequence GDEPLENYLDTEYF. This peptide has demonstrated a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits antiretroviral activity in vivo, particularly anti-HIV-1 activity. IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INFy, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response to HIV infection. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC – proteins. IPF appears to present a novel mechanism to reduce the viral burden and stimulate innate immune responses to the virus for patients with significant antiretroviral resistance.
Proprietary Cell Line Producing Clone 3 anti-HIV monoclonal antibody
The Company’s Clone 3 cell line, which produces fully human monoclonal antibodies (mAbs) that specifically target and neutralize the HIV-1 virus, is proprietary to the Company.
Pending Patent Applications
The Company has the following pending patents covering its anti-HIV monoclonal antibody technology:
Pending Patent covering the recombinant of the Clone 3 antibody. This form of the Clone 3 antibody is prepared using the known amino acid sequence of the antibody in conjunction with a high producing CHO cell line for generating recombinant form of the monoclonal antibodies that will ultimately be used in patient application.
Pending Patent coverage of small molecules (mini-peptides) for commercial use derived from the structure of the Clone 3 antibody for interrupting and preventing binding between the HIV virus and the human CD4+ cell.
Coverage is directed to blocking peptides that bind to and neutralize the HIV virus, and
Competitive peptides that bind to the target CD4+ cells at the point of virus access into the human cell to prevent infection.
Pending Patent covering the proprietary methodology for producing fully human neutralizing monoclonal antibodies against infectious diseases, including Rabies, influenza A, influenza B, Tetanus, Diphtheria, HIV-2, Anthrax, Smallpox, H1N1 influenza, Herpes Zoster, Varicella Zoster and Ebola.
Pending Patent covering the proprietary methodology for produced anti-antigen monoclonal antibodies to produce vaccines to achieve a broad and durable humoral protective antibody response against the corresponding infectious agent.
Proprietary Methodology for Producing Fully Human Monoclonal Antibodies
The Company proprietary mAb methodologies & immunotherapeutic technologies platform will be used to create therapeutics for treatments of viral infectious diseases against:
HIV-2
Anthrax
Smallpox
H1N1 Influenza
Herpes Zoster
Varicella Zoster
Ebola
The Company antibody-based immunotherapeutic platform can be utilized for both human and all animal infectious-disease applications.
In addition to the anti-HIV monoclonal antibodies produced by the Company, the Company currently has also produced fully human monoclonal antibodies against:
Rabies
Influenza A
Influenza B
Tetanus
Diphtheria
The Significance of the Methodology for Producing Fully Human Therapeutic Monoclonal Antibodies
Biologics, specifically fully human neutralizing monoclonal antibodies directed against infectious disease, is considered the new frontier in biotechnology. In the past, the initial starting products were “humanized” rat and mouse mAbs being created for therapeutic use. “Humanized” immunoglobulins are the major immunotherapeutic that is prevalent today. What sets the Company’s antibody technology apart from that employed by other pharma? The Company’s technology permits the cloning of human or animal immune system cells. With the Company’s proprietary methodologies, stable parent hybridomas cell lines can be created that produce fully human antibodies.
Enzolytics specializes in the creation of human neutralizing monoclonal antibodies, not “humanized” mouse or rat counterparts, as are many mAb therapeutics in pharmaceutical use today. The Company’s technological methodologies have developed an effective, strong, and robust portfolio of biologics that have a pharmaceutical application with significant benefits to patients or animals in the global marketplace. From an identified and created parent hybridoma cell line, four distinct and effective products can be produced: (1) fully human neutralizing monoclonal antibody—directed against any pathogen based disease entity—through use in passive immunotherapy; (2) an effective humoral active vaccine that is safe and effective; (3) an oral mini-antibody peptide-based medication with an efficacy that is equivalent to the immunologic capacity of the monoclonal antibody produced by parent hybridoma cell; and (4) an entry-fusion inhibitor that is immunologic in character and scope. The applications are broad, effective, and beneficial for immunotherapeutic use.
The methodologies and processes for creating immortalized cells that stably produce human monoclonal antibodies are Company proprietary trade secrets.
Anti-HIV Technology and Products
Using its proprietary technology, The Company has created a proprietary cell line that produces a fully human monoclonal antibody (known as Clone 3) that specifically targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). This capability to neutralize the virus means that Clone 3 may be used successfully to treat those infected with HIV and provide an ideal immunogen in the development of an active anti-HIV/AIDS vaccine that is both prophylactic and therapeutic.
Additional supplemental products may be produced as well, for example, vaginal creams for prevention of transmission of the virus. Additionally, Clone 3 has the potential to enormously reduce the incidence of mother-to-child transmission (MTCT) of the virus. Not only might it prevent in-utero viral transmission but, postnatally, effective treatment can be administered without fear of antiretroviral (ARV) toxicity or resistance.
Each of these distinct products flows from the Company’s technology. The first is the use of the antibody itself or a recombinant of the antibody. The second is the Clone 3 vaccine, the third is a mini-antibody or paratope of the Clone 3 antibody, and the fourth is a competitive binding entry-fusion inhibitor that prevents infectivity.
In addition to the Clone 3 monoclonal antibody against HIV, the Company has also created human monoclonal antibodies against other infectious diseases, including rabies, influenza A, influenza B, tetanus, and diphtheria. This immunotherapeutic technology platform can be readily applied to creating monoclonal antibodies against other pathogenic diseases, including the SARAS-CoV-2 (CoronaVirus), HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto=immune disease, and the Ebolavirus. The Company’s antibody-based Immunotherapeutics platform can be utilized across both human and animal infectious-disease applications. For example, the technology can be used to produce treatment for elephant and equine diseases that threaten these species.
?
Home
Our Mission
Our Technology
Our Science
Who We Are
Intellectual Property
Company News
Contact Us
Sitemap
© 2024 Enzolytics.
All rights reserved.
Website by web.com.
Well stated!!!
With the various IP's and the specific Pipelines we hold, I would venture to say that a Big Pharma Company would Easily be able to Buyout this company for $2.50- $5.00/Share. this little Gem is small yet playing in the major League of BP's. It is like they are a group like Lynyrd Skynyrd opening for The Who back in the day, nobody really heard of them, however, when they played a show people knew they were the Real Deal and were soon in high demand!!!
Hang on to your shares, when this hits, it is going to soar!!!
Buyout or Merger or Partnership is not out of the question!!!
Felizian Paul Biography :
Mr. Felizian Paul with his wife Alie Chang are the founders of "International Telecommunications, Inc." and its subsidiary "EarthNet Telecom, Inc." trading on the OTCBB NASDAQ under the symbol: ITS.
Mr. Paul, with more than 25 years of corporate and entrepreneurial experience, has developed and nurtured a wide network of business, professional and interpersonal relationships in Europe, China and the United States.
In recent years, he has endeavored to provide a gateway for international businesses to enter markets in China and to aid in establishing their presence there, as well as to assist companies from China to trade internationally.
Mr. Paul's diverse roles in corporate, private and community based sectors provided him skills as an entrepreneur in multi¨Ccultural deals. He was instrumental in creating new opportunities between US and China.
For the past decades, Mr. Paul also has served as Chief Executive Officer of Pac Pacific Group Int'l Inc. His entrepreneurial endeavors, business acumen and strong engineering background motivated him to form his own successful real estate development and general construction company. This company has constructed more than one million square feet of industrial complexes, resort developments, large-scale residential developments and high end custom homes. He has served as consultant to large real estate developments in Europe and has built strong relationships with the European and Asian business communities.
Through Mr. Paul's leadership, Pac Pacific Group Int'l Inc. brought National Geographic Television programs to China. As result, today NGTV is a well known brand in China and now has established its own cable channel there. Together with his wife Alie Chang, Mr. Paul produces and distributes lifestyle and home improvement / interior design television programs for China, thus enabling U.S. companies to merchandise consumer products via product placement and also leading TV viewers to their e-commerce site.
In1990's, Mr. Paul served on the Board of Directors of the Building Industry Association of Los Angeles and has served on the Board of BIA, State of California. These organizations are affiliated with the National Association of Home Builders (NAHB), the single largest association in the US.
Mr. Paul's companies have been publicly commended by the State of California as well as Mayor of the City of Los Angeles for their outstanding achievements and contributions to the economy of the City of Los Angles as well as the State of California.
In 2001, Mr. Paul and his company brought more than 70 U.S. companies to participate in Shanghai Expo. In 2003, Mr. Paul also successfully organized over 25 US companies to participate at the "Beijing Procurement Expo for the Olympics". These two events won them high recognition NAHB and the U.S. Department of Commerce.
Among other community and social organizations, Mr. Paul is on the Advisory board of China Affairs to the Pacific Rim Chamber of Commerce.
After the Katrina disaster, Mr. Paul was recently appointed to be on the Advisory Board of the ECA (Enterprise Communication Association), on Disaster Preparedness.
Felizian Paul Colleagues :
Name Title Email
Willy Chang
Dir. - Marketing, Shanghai Office, China Please login
Alie Chang
Dir., CEO, Pres. Please login
John Callaci
Dir., CTO, Chief Scientist Please login
Klaus Hilgers
Dir., Business Management Please login
Hou Haibin
h ttps://markets.businessinsider.com/news/stocks/trump-media-spac-djt-ceo-letter-congress-naked-short-sellers-2024-4
h ttps://youtu.be/SVgVzEVeP4Q?feature=shared
This IS the future!!!
Well said! this is the true sentiment of all DLOC shareholders. Please don't string us along like ENZC shareholders were and are. We Need Proof!!!
A buyout at $2.50-$5.00/share for the entire pipeline would be a sweet deal for a BP company looking to expand their horizons
I saw Carlos Santenna a few years back, sorry about my southern draw 😀😀😀
i agree as well. there is a lot of potential for this stock to rocket past the low orbiting Earth satellites it will be using to change the paradigm. GLTA
Very possible!!! i would take anything over $1.00 but do believe with this company's pipeline that we could see a buyout offer come in at $4.25, this would set the stage for a rally up to $5.00/ share and then instituitional buyers like Baker Bros Advisors LLC to purchase 15% of the float.
(there is nothing wrong with having Faith in your hopes) :) <*(( ))><
good time to average down. the only thing that could ruin this is the infamous Reverse Split, which fortunately, has not been mentioned as of yet. LONG AND STRONG, adding at these levels could possibly yield a great ROI glta
i did the same and chose DLO*C and RSP*i both with potentially explosive ENZC type runs when we were @.95/share.
Thank You for that information about AON orders Tom, much apprectiated!
oh, ok makes sense. mystery solved, Thank You AJD!
i want to pose a question to the board, anyone who can answer i would appreciate it. it has to do with the i-hub app. when i press "trades" to see the buy and sells, the buys are green, the sells are red, and then there are thes "black" trades in the collumn with the colors it is displayed as such B/?/S
what does the ? represent what does the black represent? Short sales? dilution? if anyone knows please feel free to comment, Thanks in advance :)
looking good, small float, This is on the launch pad, a coiled spring, ready to be sent into "orbit" no pun intended lol
Share Structure Looking Good, this could move Swiftly given the right circumstances!!!
?
Skip to content
?
Posted inMilitary
DoD interested in smartphone-to-satellite communications services
The Commercial Services Communications Office is working on a solicitation for direct-to-device satellite communications services to be released later this year
Sandra Erwin March 1, 2023
Click to share on X (Opens in new window)
Click to share on Facebook (Opens in new window)
Click to share on LinkedIn (Opens in new window)
Click to share on Reddit (Opens in new window)
Click to email a link to a friend (Opens in new window)
Click to share on Clipboard (Opens in new window)
? iPhone 14 smartphones are able to communicate with Globalstar satellites, primarily for emergency messaging. Credit: Apple
WASHINGTON — The technology race to connect cellphones to satellite networks has not gone unnoticed by the Defense Department.
“That capability is exciting to us,” Clare Grason, head of the Pentagon’s commercial satellite communications office, said Feb. 28.
Emerging communications services that connect phones directly to satellites are attractive to military users that operate in locations where there is no cellular network connectivity, Grason said during a FedInsider webinar.
“This would enable the DoD to equip warfighters with smaller, lighter, more capable and inexpensive communication devices,” she said. “Some of the architectures will enable existing smartphones to seamlessly communicate with satellites using cellular spectrum.”
Grason’s office, known as CSCO, is working on a solicitation for direct-to-device satellite communications services to be released later this year. “This is something for the industry to keep their eyes open for,” she said. The CSCO is also seeking feedback from military users. “We’re in the market research stage,” Grason said.
A number of companies have entered the direct-to-cell race, including Iridium, Lynk Global, AST SpaceMobile, Samsung, Globalstar and others.
Contracts coming for PLEO and micro GEO
Grason said DoD is looking to diversify the types of satellite communications services it buys from the private sector.
As early as May, the CSCO plans to award contracts for satcom services provided by low Earth orbit internet companies. Multiple bids were received in November, said Grason. “We are wrapping up the source selection.”
LEO satcom is a departure from the traditional geosynchronous (GEO) communications satellite services. Grason said military users are demanding low-latency, broadband services from the likes of OneWeb, SpaceX and Amazon.
DoD also is interested in LEO satcom services and those provided by small GEO satellites
DoD will still continue to rely on GEO services, said Grason. “LEO is great but I don’t think it is the most important regime. I think all orbits have important attributes that the DoD needs to take advantage of.”
There is also growing interest in satcom services that use small GEO satellites, such as those offered by Astranis.
“That’s one of the innovations taking place in GEO,” Grason said. “Micro-GEO is one-tenth the size of traditional GEO birds and we are seeing those as having an advantage for the DoD, and we want to set up contract vehicles to access the capabilities.”
She said her office is making an effort to work with as broad a sector of the market as possible. “A lot of times the inhibitor to taking advantage of what the commercial marketplace has to offer is the bureaucracy,” he said. “CSCO is trying to take that burden away by having very flexible contract vehicles ready to go.”
Military satcom vs commercial
Grason said DoD will always own and operate its own communication satellites but that capacity is limited and often restricted to “priority” users, whereas commercial services are accessible for any military customer able to pay for them.
Military satcom is subject to a “prioritization scheme,” she said. “Missions that are toward the bottom of that hierarchy, they don’t simply have access to capability when they may need it. By contrast, commercial satcom is pay to play. If you have funding and there is an availability in the commercial sector, we can facilitate a deal for you.”
Grason said commercial companies offer managed services that give customers autonomy over how the network is operated. “That arrangement has been very attractive, particularly for the customers who don’t quite have the rank on that prioritization scheme,” she said.
DoD continues to buy a substantial amount of “transponded” capacity under leasing arrangements with commercial satcom operators, “but over time, that approach will lessen as commercial industry will not be selling access to their systems by the megahertz,” Grason said.
Newer systems like SpaceX’s Starlink do not lease capacity but provide full services under agreements similar to what DoD currently has with Iridium. “How you buy it is going to help determine how efficient you are in using what you have acquired,” she added.
The U.S. Army is now reviewing proposals for managed satcom services and will conduct a pilot program, said Grason. “Based on the outcome of that pilot program, the intent is to issue an enduring long-term contract based on the satcom-as-a-service model.” She said service packages can be tailored based on needs and budget constraints.
Before they can compete for a DoD contract, commercial satcom providers are vetted in a number ways, including their cybersecurity practices and supply chain.
“We scrutinize their financial reporting, we thoroughly investigate the condition of their supplier base, what trade sanctions perhaps are being levied on them or their network, and really a host of other commercial concerns,” said Grason. “These are all things that we weigh pretty heavily when doing business with what is essentially a multinational global supplier base.”
Related
?
Viasat links up with Northrop Grumman for Air Force communications experiment
?
New report recommends Space Force change how it buys commercial satellite services
?
DoD’s satcom evolution
direct-to-cellLEOSatcom
?
Sandra Erwin
Sandra Erwin writes about military space programs, policy, technology and the industry that supports this sector. She has covered the military, the Pentagon, Congress and the defense industry for nearly two decades as editor of NDIA’s National Defense... More by Sandra Erwin
Click to share on X (Opens in new window)
Click to share on Facebook (Opens in new window)
Click to share on LinkedIn (Opens in new window)
Click to share on Reddit (Opens in new window)
Click to email a link to a friend (Opens in new window)
Click to share on Clipboard (Opens in new window)
Upcoming Events
all events >>
Mar 18
Satellite 2024
Mar 18
2nd International Summit on Gravitation, Astrophysics and Cosmology
Mar 18
From Terrestrial to Celestial: Unlocking the potential to enhance US-Latin American B2B collaboration
Mar 20
AAS Goddard Space Science Symposium
Mar 21
Aerospace – 2024
?
Sign up for a SpaceNews newsletter
Get top stories, military space news and more delivered to your inbox.
Subscribe to newsletters
Back to top
?
About
About SpaceNews
Advertise
Subscribe
Sign up for Our Newsletters
Subscribe to the Magazine
Get Magazine Reprints
Events
View Events Calendar
Submit Your Event
Follow us on
Facebook Page
X
LinkedIn
YouTube
RSS Feed
SpaceNews © 2023. All Rights Reserved. Privacy PolicyTerms & Conditions
the solution to polution is dilution in terms of water, however in terms of stock, it is a killer of SP
all we need is ONE powerful PR that creates a feeding frenzie with Volume that will exceed the Low Earth Orbiting Satelites we know we will be connecting with!!!
.005.......0075,.....013,.....057...,.14,... .25
...... .45........ .75......... 1.09,......2.56.....5.43
.....12.........15............28...........37........52.....................60..........73........ $123
it all starts as a thought
just part of the problem low bidding like that.then to brag about it to longs that hold positions that have been pulverised. some things are better left unsaid, but to each his own, i guess some folfs need validation that they are a "good trader" others silently trade
what are the outstanding shares?
could be setting up for an Epic run, the mother of all runs!!! wikl make ENZC look like a gnat in comparison. Keep the Faith Longs,this one could be a zipcode changer!
This hidden Gem is starting to come to life, would be wise to take advantage of these low prices while it is still down at these levels.
brutal is right. blood bath is more accurate.
one Tweet on X From Elon endorsing or Supporting DLOC would have Monumental impact on this little Gem's SP.
All things are possible, if you keep the faith!!!
HOLD............Acumulate.............keep the Faith.......
Volatility
RSPI
Volatility, measured using the width of the Bollinger Bands®, is extremely low, resulting in a condition called the Bollinger Band Squeeze. Bollinger Band Squeezes tend to precede major price breakouts, although they do not predict which direction the new trend will take. Trend and momentum indicators can be useful during Squeeze conditions to help discern the direction of future trends.
Respirerx Pharmaceut RSPI: OTC Markets
Pharmaceuticals
$0.0010$0.0000(0.00%)
Market open: 9:50:30 AM ET, 03/07/2024
Bid/Size
$0.0009/75,952
Ask/Size
$0.0010/40,000
Previous close
$0.0010
Today's open
$0.0009
Today's volume
6MBelow Avg.
Today's range
$0.0009$0.0010
52-week range
$0.0006$0.0191
i agree Tedpeele. I am hoping we can get an update on the progress soon as otc investors are short sighted and lose interest if the stock is not moving north!!!
just as i suspected..so...i picked up more shares. i will hold this as long as it takes!!!
lets see how this plays out ....sell the news js par for the course, expect .0017.... i will buy more then...
opportunity to buy new shares that ultamitly water down Shareholder Value.
my strategy at this point, hold & Pray
this is where the rubber meets the road, patents are not in question, but "Where's The Beef" ???
would love to get some news on a prototype!!!!
Accumulating......
massive conversions or dilution!!! nothing like crapping on your shareholders
they will push it a little past .02cents then short it back down to a little under .01 cent.
and cover for a 100% gain. it is the playbook.
Typical shananagins against gullable investors like myself who still believe that there is still honesty in the stock market.
My Shirt reads.
"I used to be a people person, then people ruined it"
my theory:
when certain people show up on this board, (and i will not mention any names, but they were present on other stocks i had shares in)
this occurs. the stock takes a little rise, people get excited bc of the positive words and intriguing theories and purchase shares, however said person sells imaginary or real shares i'm not sure, lets say 999,999 shares short, then buys to cover once other naysayers or in collusion with or actual MM's beat the SP down to demoralize longs into selling their devalued stock.
How far away are we from an actual working product?
with the share price so low, why hasn't there been people flocking to this stock? is it just under the radar, or is there something we newbies should know about this company. has a good story but are these just pipe dreams or is this a legit company with a real possibility at making it to the Bigtimes
???????
lots of volume, lots of sells=conversions or dilution. bottom line = pretty crappy SP.
Would be nice to see some further updates